Cellceutix Corp. has selected Dr. Reddy's Laboratories to manufacture Prurisol, its new drug candidate for the treatment of psoriasis. Dr. Reddy's will manufacture Prurisol for oral dosing for Phase II/III trials, which will begin upon completion of the manufacturing.
 
"We have great expectations for this drug because it performed amazingly in lab studies. Our research showed Prurisol to be much more effective than methotrexate, a standard of care treatment for advanced psoriasis. We wanted to use only a world-class manufacturer and Dr. Reddy’s is internationally renowned for its excellence in research, manufacturing and distribution," said Leo Ehrlich, chief executive officer at Cellceutix. "As we continue to emerge as a leading drug developer, we are committed to working with companies and organizations that have high standards and a strong reputation. Dr. Reddy’s is a perfect fit for Prurisol. Prurisol has a complex process for synthesizing and manufacturing in oral form and we are very pleased to have Dr. Reddy’s handling those formulations."